Riskpilot← Back to searchSign inGet full accessNorthX Biologics AB
ABActiveOrg 5566617816Storjordenvägen 2Manufacture of pharmaceutical preparations · NACE 2120Est. 2004116 employees
Revenue 2024
SEK 181,8M
+66% vs 2023
EBITDA margin
-22.5%
+35% vs 2023
Equity ratio
0.4%
Financial strength
Net profit 2024
SEK -52,2M
-1068% vs 2023
| Revenue | SEK 181,8M | +66% |
| EBITDA | SEK -41M | +35% |
| Net profit | SEK -52,2M | -1068% |
| Total assets | SEK 331M | -8% |
| Equity | SEK 1,2M | -97% |
| Employees | 116 | — |
Legal name
NorthX Biologics AB
Org number
5566617816
Legal form
Aktiebolag
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
29 april 2004
Share capital
SEK 100 000
Employees
116 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas i förening av ledamöterna Firman tecknas av en av ledamöterna i förening med suppleanten
Company purpose
Bolaget ska direkt eller indirekt bedriva utveckling och tillverkning av läkemedelsprodukter och därmed förenlig verksamhet.
Address
Storjordenvägen 2
Phone
+4660641670
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 89 564 | 138 549 | 158 938 | 109 499 | 181 846 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −34 914 | −22 440 | −4 336 | −62 600 | −41 000 |
| Depreciation & amort. | −5 777 | −8 969 | −6 829 | −11 913 | −16 514 |
| EBIT | −40 691 | −31 409 | −11 165 | −74 513 | −57 514 |
| Net financials | −590 | −428 | −579 | 758 | 56 |
| Profit before tax | −33 781 | −31 837 | −11 743 | −4 468 | −52 191 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −33 781 | −31 837 | −11 743 | −4 468 | −52 191 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 182 832 | 221 448 | 276 411 | 359 201 | 330 998 |
| Equity | 8 081 | 2 143 | 7 900 | 46 432 | 1 241 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 174 751 | 219 305 | 268 511 | 312 769 | 329 649 |
| Total debt | 174 751 | 219 305 | 268 511 | 312 769 | 329 649 |
EBITDA margin
-22.5%
This company
15.8%
Market median
-242% vs market
20202024
Equity ratio
0.4%
This company
38.2%
Market median
-99% vs market
20202024
Return on equity
-4205.6%
This company
18.4%
Market median
-22957% vs market
20202024
Net profit margin
-28.7%
This company
8.1%
Market median
-454% vs market
20202024
Asset turnover
0.55×
This company
1.12×
Market median
-51% vs market
20202024
Debt / equity
265.72×
This company
0.62×
Market median
-42758% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
RJ Chief Auditor | Chief Auditor | 2020 |
| Former (2) | ||
LC Chief Executive Officer | Chief Executive Officer | 2022 – 2022 |
AC Chief Auditor | Chief Auditor | 2021 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2022 | |
| Chairman | 2022 | |
| Deputy Board Member | 2026 | |
| Former (7) | ||
| Chairman | 2021 – 2022 | |
| Deputy Board Member | 2022 – 2026 | |
| Board of Directors | 2020 – 2022 | |
| Board of Directors | 2022 – 2023 | |
| Chairman | 2020 – 2021 | |
| Deputy Board Member | 2022 – 2026 | |
| Chairman | 2020 – 2020 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Flerie Invest AB
NorthX Biologics AB Board members of NorthX Biologics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lars Christer Fahlander | Chief Executive Officer | 0 companies |
| Robert Jan Hasslund | Chief Auditor | 0 companies |
| Ann Charlott Bouvin | Chief Auditor | 0 companies |
| Adriana Jannetje Hoogstraate | Board of Directors | 0 companies |
| Wilhelmus Johannes Antonius Maria Frieling | Chairman | 0 companies |
| Ted Ingemar Jakob Fjällman | Deputy Board Member | 0 companies |
| Maria Ingrid Rynell | Chairman | 0 companies |
| Jon Galli | Board of Directors | 0 companies |
| Ida Helena Christina Strigård | Board of Directors | 0 companies |
| James Kelly Ganjei | Chairman | 0 companies |
| Lars Peter Boman | Deputy Board Member | 0 companies |
| Peter Alistair Coleman | Chairman | 0 companies |
| Sara Eva-Karin Sällstedt Gidlund | Deputy Board Member | 0 companies |